2021
DOI: 10.1016/j.nefroe.2022.01.004
|View full text |Cite
|
Sign up to set email alerts
|

Peritoneal dialysis in an adult patient with myelomenigocele and ventriculoperitoneal shunt

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…Clinical identification of LN can be challenging, being commonly discovered after careful examination of urine and renal function tests [1,3]. Monitoring the activity and/or control of LN is essential to prevent the progression of chronic kidney disease, which can have a negative impact on quality of life, functional dependence, comorbidities, and mortality risk [4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…Clinical identification of LN can be challenging, being commonly discovered after careful examination of urine and renal function tests [1,3]. Monitoring the activity and/or control of LN is essential to prevent the progression of chronic kidney disease, which can have a negative impact on quality of life, functional dependence, comorbidities, and mortality risk [4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…The current therapeutic consensus suggests a clone-directed approach in case of MGRS-associated renal disease, i.e., antimyeloma agents in patients with plasma cell clones, rituximab-containing regimens in patients with lymphocytes or lymphoplasmacytic clone [ 5 ]. Treatment should also primarily aim to protect against the risk of progression to end-stage chronic kidney disease (ESRD), which brings high functional dependence, low quality of life and high risk of mortality [ 5 , 14 16 ]. The prevention of thrombotic and infectious risk should be performed in cases of nephrotic syndrome, proteinuria and hypertension should be controlled, preferably with blockers of the renin-angiotensin system, and bicarbonate, phosphate and vitamin D supplements should be administered in patients with FS to prevent osteomalacia [ 5 ].…”
Section: Introductionmentioning
confidence: 99%